Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial

被引：0

作者：

Kim, H. ^{[1
]}

Park, S. ^{[2
]}

Kim, T. M. ^{[3
]}

Han, J-Y. ^{[4
]}

Lee, G-W. ^{[5
,6
]}

Shim, B. Y. ^{[7
]}

Lee, Y-G. ^{[8
]}

Kim, S-W. ^{[9
]}

Ock, C-Y. ^{[10
]}

Hwang, S. ^{[11
]}

Lee, Y. ^{[12
]}

Kim, R. ^{[13
]}

Jung, H. A. ^{[14
]}

Sun, J-M. ^{[15
]}

Lee, S-H. ^{[16
]}

Ahn, J. S. ^{[15
]}

Ahn, M-J. ^{[17
]}

机构：

[1] Samsung Med Ctr SMC, Hematooncol, Seoul, South Korea

[2] Samsung Med Ctr SMC, Hematol & Med Oncol, Seoul, South Korea

[3] Seoul Natl Univ, Internal Med Dept, Coll Med, Yeongeon Med Campus, Seoul, South Korea

[4] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Ctr Lung Canc, Goyang, South Korea

[5] Gyeongsang Natl Univ Hosp, Internal Med Dept, Jinju, South Korea

[6] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea

[7] Catholic Univ Korea, Dept Internal Med, St Vincents Hosp, Suwon, South Korea

[8] Kangbuk Samsung Hosp, Samsung Med Ctr SMC, Dept Internal Med, Seoul, South Korea

[9] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[10] Lunit Inc, Med Affairs, Oncol Grp, Seoul, South Korea

[11] Lunit, Med Affairs, Oncol Grp, Seoul, South Korea

[12] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea

[13] Inocras, Oncol Dept, San Diego, CA USA

[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Hematol Oncol,Dept Med, Seoul, South Korea

[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Med, Seoul, South Korea

[16] Samsung Med Ctr SMC, Med Oncol, Seoul, South Korea

[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Hematol Oncol Dept, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

631P

引用

页码：S1636 / S1636

页数：1

共 50 条

[41] PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy
Prabhash, K.
Noronha, V.
Patil, V.
Joshi, A.
Chougule, A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S395 - S395
[42] Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results
Wakelee, Heather
Patel, Jyoti D.
Heist, Rebecca
Balmanoukian, Ani
Besse, Benjamin
Felip, Enriqueta
Carcereny Costa, Enric
Chow, Laura Q.
Koczywas, Marianna
Garassino, Marina C.
Christoph, Daniel
Toh, Chee Keong
Johnson, Melissa L.
Chaft, Jamie
Kurata, Takayasu
Qiu, Jiaheng
Kowanetz, Marcin
Coleman, Shelley
Mocci, Simonetta
Sandler, Alan
Gettinger, Scott N.
Peters, Solange
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S251 - S252
[43] Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study
Zhou, Qing
Xu, Chong-Rui
Cheng, Ying
Liu, Yun-Peng
Chen, Gong-Yan
Cui, Jiu-Wei
Yang, Nong
Song, Yong
Li, Xiao-Ling
Lu, Shun
Zhou, Jian-Ying
Ma, Zhi-Yong
Yu, Shi-Ying
Huang, Cheng
Shu, Yong-Qian
Wang, Zhen
Yang, Jin-Ji
Tu, Hai-Yan
Zhong, Wen-Zhao
Wu, Yi-Long
CANCER CELL, 2021, 39 (09) : 1279 - +
[44] Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR plus mNSCLC)
Yoh, K.
Atagi, S.
Reck, M.
Garon, E. B.
Aix, S. Ponce
Moro-Sibilot, D.
Winfree, K. B.
Frimodt-Moller, B.
Zimmermann, A. H.
Visseren-Grul, C. M.
Nakagawa, K.
ANNALS OF ONCOLOGY, 2019, 30
[45] Retrospective Analysis of Patients Treated with Radiosurgery for 4 Brain Metastases from ALK Rearranged and EGFR Mutated NSCLC
Wang, Yan
Calbat, Courtney L.
Gomez, Daniel R.
Li, Jing
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : E38 - E38
[46] Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
Kenmotsu, Hirotsugu
Sakai, Kazuko
Mori, Keita
Kato, Terufumi
Sugawara, Shunichi
Kirita, Keisuke
Yoneshima, Yasuto
Azuma, Koichi
Nishino, Kazumi
Teraoka, Shunsuke
Koyama, Ryo
Masuda, Ken
Hayashi, Hidetoshi
Toyozawa, Ryo
Miura, Satoru
Sato, Yuki
Nakagawa, Kazuhiko
Yamamoto, Nobuyuki
Nishio, Kazuto
Takahashi, Toshiaki
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
[47] Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Tao Jiang
Pingyang Wang
Jie Zhang
Yanqiu Zhao
Jianying Zhou
Yun Fan
Yongqian Shu
Xiaoqing Liu
Helong Zhang
Jianxing He
Guanghui Gao
Xiaoqian Mu
Zhang Bao
Yanjun Xu
Renhua Guo
Hong Wang
Lin Deng
Ningqiang Ma
Yalei Zhang
Hui Feng
Sheng Yao
Jiarui Wu
Luonan Chen
Caicun Zhou
Shengxiang Ren
Signal Transduction and Targeted Therapy, 6
[48] Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Jiang, Tao
Wang, Pingyang
Zhang, Jie
Zhao, Yanqiu
Zhou, Jianying
Fan, Yun
Shu, Yongqian
Liu, Xiaoqing
Zhang, Helong
He, Jianxing
Gao, Guanghui
Mu, Xiaoqian
Bao, Zhang
Xu, Yanjun
Guo, Renhua
Wang, Hong
Deng, Lin
Ma, Ningqiang
Zhang, Yalei
Feng, Hui
Yao, Sheng
Wu, Jiarui
Chen, Luonan
Zhou, Caicun
Ren, Shengxiang
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[49] A biomarker study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043
Watanabe, Satoshi
Furuya, Naoki
Nakamura, Atsushi
Shiihara, Jun
Nakachi, Ichiro
Tanaka, Hisashi
Nakao, Mika
Minato, Koichi
Seike, Masahiro
Sasaki, Shinichi
Kisohara, Akira
Takeuchi, Susumu
Honda, Ryoichi
Takamura, Kei
Ling, Yiwei
Okuda, Shujiro
Kagamu, Hiroshi
Yoshimura, Kenichi
Kikuchi, Toshiaki
Kobayashi, Kunihiko
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202.
Bhatia, Aarti K.
Flamand, Yael
Johnson, Jennifer Maria
Ishizuka, Jeffrey Joseph
Duan, Fenghai
Tang, Mei
Karivedu, Vidhya
Subramaniam, Rathan M.
Burtness, Barbara
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →